Table 4.
Univariate and multivariate Poisson regression with death for all-causes as the outcome
| Univariate model | Multivariate model | ||||
|---|---|---|---|---|---|
| Variables | Categories | RR | 95% CI | RR* | 95% CI |
| Gender | Male vs Female | 1.55 | (1.42-1.70) | 1.24 | (1.12-1.36) |
| Age at enrolment (years) | 18-34 | Ref. | Ref. | ||
| 35-44 | 0.96 | (0.88-1.06) | 1.53 | (1.36-1.71) | |
| 45-54 | 1.28 | (1.12-1.47) | 2.41 | (2.05-2.83) | |
| 55-64 | 1.56 | (1.27-1.92) | 2.66 | (2.13-3.33) | |
| ≥65 | 3.06 | (2.24-4.19) | 5.41 | (3.89-7.52) | |
| Year of enrolment | 1986-1989 | 2.41 | (1.99-2.91) | 1.55 | (1.25-1.94) |
| 1990-1993 | 2.23 | (1.84-2.70) | 1.43 | (1.15-1.78) | |
| 1994-1997 | 1.63 | (1.34-1.98) | 0.89 | (0.71-1.10) | |
| 1998-2001 | 1.23 | (1.00-1.51) | 1.11 | (0.90-1.36) | |
| 2002-2005 | 1.01 | (0.81-1.27) | 1.00 | (0.80-1.26) | |
| 2006-2012 | Ref. | Ref. | |||
| IDUs | Yes vs No | 1.76 | (1.62-1.90) | 1.54 | (1.40-1.70) |
| AIDS-event | Yes vs No | 17.55 | (16.22-18.99) | 3.75 | (3.43-4.11) |
| HBV/HCV co-infection | Yes vs No | 0.95 | (0.89-1.03) | ||
| CD4 cell count, cell/mm3 | 0-49 | 44.92 | (37.90-53.25) | 4.10 | (3.62-4.65) |
| 50-99 | 17.58 | (14.48-21.33) | 2.73 | (2.36-3.16) | |
| 100-199 | 7.78 | (6.45-9.39) | 1.83 | (1.62-2.08) | |
| 200-349 | 3.02 | (2.45-3.67) | 1.47 | (1.31-1.65) | |
| 350-499 | 1.64 | (1.32-2.04) | 1.15 | (1.01-1.30) | |
| ≥500 | Ref. | Ref. | |||
| Antiretroviral therapy | cART | Ref. | Ref. | ||
| Subobtimal cART | 3.26 | (2.91-3.65) | 2.18 | (1.95-2.44) | |
| No therapy | 2.14 | (1.96-2.33) | 8.19 | (7.23-9.27) | |
| Cancer occurrence | Without cancer | Ref. | Ref. | ||
| ADC | 14.60 | (12.51-17.03) | 1.22 | (1.08-1.38) | |
| NADC | 10.48 | (8.49-12.93) | 1.29 | (1.12-1.50) | |
Time-dependent Poisson regression models, with observational period divided into intervals of 1-year duration. Gender, age at enrolment, year of enrolment, intravenous drug use as risk factors and hepatitis C or B virus co-infection were included in the model as fixed covariates. CD4 cell count, AIDS events (ADC was not considered as an AIDS event), antiretroviral therapy and cancer occurrence were included as time-dependent covariates, considering at enrolment and every year.
*Adjusted for all the variables in the model.
Abbreviations: RR relative risk, 95% CI 95% confidence interval, IDUs intravenous drug users, HBV/HCV co-infection hepatitis B virus/hepatitis C virus positivity, cART combined antiretroviral therapy.